Long-term treatment of patients with HIV-1: the role of atazanavir
Miguel Ángel Artacho1, Pablo Barreiro2, José Vicente Fernández-Montero2
1Department of Internal Medicine, Hospital Universitario Gregorio Marañón, Madrid, Spain; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
Background: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years.
Objective: To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.
Methods: Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines.
Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.
Keywords: atazanavir, HAART, protease inhibitors
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]